Liposomal cancer chemotherapy: current clinical applications and future prospects

Bibliography

• BANGHAM AD, STANDISH HM, WATKINS JC: Diffusion of univalent ions across the lamellae of swollen phospholipids. j Mol. Biol. (1965) 13:238–252.
   PubMed Web of Science ®Google Scholar
• GREGORIADES G, SWAIN CI WILLS EJ, TAVILL AS: Drug-carrier potential of liposomes in cancer chemotherapy. Lancet (1974) 1:1313–1316.
   PubMed Web of Science ®Google Scholar
• •Identification of the potential role of liposomes in cancer chemotherapy.
   Google Scholar
• GREGORIADIS G: The carrier potential of liposomes in biology and medicine (first of two parts). N Engl. J. Med. (1976) 295:704–710.
   PubMed Web of Science ®Google Scholar
• GREGORIADIS G: The carrier potential of liposomes in biology and medicine (second of two parts). N Engl. j. Med. (1976) 295:765–770.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, LEWANSKI CR, STEWART JSW: Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development. CBI]. arca (1?. Coll. Radial) (2000) 12:2–15.
   Google Scholar
• TURNER AF, PRESANT CA, PROFFITT RT et al.: In-111-labelled liposomes: dosimetry and tumour depiction. Radiology (1988) 166:761–765.
   PubMed Web of Science ®Google Scholar
• PRESANT CA, PROFFITT RT, TURNER AF et al.: Successful imaging of human cancer with Indium-111-labelled phospholipid vesicles. Cancer (1988) 62:905–911.
   PubMed Web of Science ®Google Scholar
• PRESANT CA, BLAYNEY D, PROFITTRT et al.: Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet (1990) 335:1307–1309.
   PubMed Web of Science ®Google Scholar
• KUBO A, NAKAMURA K, SAMMIYA Tet al: Indium-111-labelled liposomes: dosimetry and tumour detection in patients with cancer. Eur. j. Nucl. Med. (1993) 20:107–113.
   PubMedGoogle Scholar
• KHALIFA A, DODDS D, RAMPLING R,PATERSON J, MURRAY T: Liposome' distribution in malignant glioma: Possibilities for therapy. Nucl. Med. Commun. (1997) 18:17–23.
   PubMed Web of Science ®Google Scholar
• ZUCCHETTI M, BOIARDI A, SILVANI A, PARISI I, PICCOLROVAZZI S, D'INCALCI M: Distribution of daunorubicin and daunorubicinol in human glioma tumours after administration of liposomal daunorubicin. Cancer Chemother. Phannacol (1999) 44:173–176.
   PubMed Web of Science ®Google Scholar
• GABIZON A, CATANE R, UZIELY B et al.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polethylene-glycol coated liposomes. Cancer Res. (1994) 54:987–992.
   PubMed Web of Science ®Google Scholar
• NORTHFELT DW, MARTIN FJ, WORKING P et al: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localisation, and safety in patients with AIDS-related Kaposi's sarcoma. j. CBI]. Phannacol (1996) 36:55–63.
   Web of Science ®Google Scholar
• SYMON Z, PEYSER A, TZEMACH D et al.: Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer (1999) 86:72–78.
   PubMed Web of Science ®Google Scholar
• KOUKOURAKIS MI, KOUKOURAKI S, GIATROMANOLAKI A et al.: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. j. Clin. arca (1999) 17:3512–3521.
   PubMed Web of Science ®Google Scholar
• •The first published trial of concomitant chemoradiotherapy using a liposomal agent.
   Google Scholar
• KOUKOURAKIS MI, KOUKOURAKI S, GIATROMANOLAKI A et al.: High intratumoural accumulation of stealth liposomal doxorubicin in sarcomas - rationale for combination with radiotherapy. Acta arca (2000) 39:207–211.
   Google Scholar
• KOUKOURAKIS MI, KOUKOURAKI S, FEZOULIDIS I et al.: High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br j. Cancer (2000) 83:1281–1286.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, MOHAMMADTAGHI S, USTER PS et al.: Effective targeting of solid tumours in patients with locally advanced cancers by radiolabelled pegylated liposomes. CBI]. Cancer Res. (2001) 7:243–254.
   PubMed Web of Science ®Google Scholar
• ••A detailed analysis of the pharmacokineticsand biodistribution of pegylated liposomes in patients with head and neck, breast and lung cancers.
   Google Scholar
• EMBREE L, GELMON KA, LOHR A et al.: Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non small-cell lung cancer patients. j Phann. Li. (1993) 82:627–634.
   PubMed Web of Science ®Google Scholar
• COWENS JW, CREAVEN PJ, GRECO WR et al.: Initial clinical (Phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. (1993) 53:2796–2802.
   PubMed Web of Science ®Google Scholar
• BATIST G, WINER E, NAVARI R, ROVIRA D, AZARNIA N AND THE TLC D-99 STUDY GROUP: Decreased cardiac toxicity by TLC D-99 (liposome encapsulated doxorubicin) vs. doxorubicin in a randomised trial of metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. Oncol. (1998) 17:115a (Abstract 443).
   Google Scholar
• BATIST G, RAO SC, RAMAKRISHNAN G et al.: Phase III study of liposome-encapsulated doxorubicin (TLC D-99) versus doxorubicin (DOX) in combination with cyclophosphamide (CPA) in patients with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. OncoL (1999) 18:127a (Abstract 486).
   Google Scholar
• HARRIS L, WINER E, BATIST G etal.:Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (Dox) in patients with metastatic breast carcinoma (MBC). Proc. Am. Soc. Clin. OncoL (1998) 17:124a (Abstract 474).
   Google Scholar
• CHEUNG TW, REMICK SC, AZARNIA N, PROPER JA, BARRUECO JR, DEZUBE BJ: AIDS-related Kaposi's sarcoma: a Phase II study of liposomal doxorubicin. The TLC D-99 Study Group. Clin. Cancer Res. (1999) 5:3432–3437.
   Google Scholar
• SHAPIRO CL, ERVIN T, WELLES L, AZARNIA N, KEATING J, HAYES DF: Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group. OncoL (1999) 17:1435–1441.
   Google Scholar
• VALERO V, BUZDAR AU, THERIAULT RL etal.: Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. j Clin. OncoL (1999) 17:1425–1434.
   Google Scholar
• WINER E, BATIST G, BELT R, GUTHEIL J, PARK Y, WELLS L: Reduced cardiotoxicity of liposome-encapsulated doxorubicin (TLC D-99) compared to free doxorubicin in first-line therapy of metastatic breast cancer in patients at increased risk for anthracycline-induced cardiac toxicity. Proc. Am. Soc. Clip. OncoL (2000) 19:64a (Abstract 323).
   Google Scholar
• GILL PS, ESPINA BM, MUGGIA F et al.:Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. OncoL (1995) 13:996–1003.
   Google Scholar
• PRESANT CA, SCOLARO M, KENNEDY P et al.: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet (1993) 341:1242–1243.
   PubMed Web of Science ®Google Scholar
• MONEY-KYRLE JF, BATES E READY Jet al.: Liposomal daunorubicin in advanced Kaposi's sarcoma: a Phase II study. Clin. OncoL (1?. Coll. Radiol) (1993) 5:367–371.
   Google Scholar
• UTHAYAKUMAR S, BOWER M, MONEY-KYRLE J et al.: Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS (1996) 10:515–519.
   PubMed Web of Science ®Google Scholar
• GIRARD PM, BOUCHAUD 0, GOETSCHEL A et al.: Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. AIDS (1996) 10:753–757.
   Google Scholar
• GILL PS, WERNZ J, SCADDEN DT et al.: Randomised Phase III trial of liposomal daunorubicin versusdoxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma. j Clin. OncoL (1996) 14:2353–2364.
   PubMed Web of Science ®Google Scholar
• •Randomised trial demonstrating equivalence between liposomal daunorubicin and combination chemotherapy.
   Google Scholar
• CORTES J, O'BRIEN S, ESTEY E, GILES E KEATING M, KANTARJIAN H: Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest. New Drugs (1999) 17:81–87.
   PubMed Web of Science ®Google Scholar
• STEELE JPC, O'DOHERTY CA, EVANS M et al.: Phase I/II trial of liposomal daunorubicin in malignant mesothelioma. Proc. Am. Soc. Clip. OncoL (1998) 17:502a (Abstract 1933).
   Google Scholar
• YEO W, CHAN KK, MUKWAYA G et al.: Phase II studies with DaunoXome in patients with non-resectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. Cancer Chemother. PharmacoL (1999) 44:124–130.
   PubMed Web of Science ®Google Scholar
• DANIELE B, DE VIVO R, PERRONE F et al.: Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis. AntiCancer Res. (2000) 20:1249–1251.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, LOPEZ-BERESTEIN G, LAUTERSZTAIN J et al.: Phase I clinical and pharmacology study of liposome-entrapped cis-bis-neodecanoato trans-RR-1,2 diaminocyclohexane platinum (II). Cancer Res. (1990) 50:4254–4259.
   PubMed Web of Science ®Google Scholar
• VADIEI K, SIDDIK ZH, KHOKHAR AR,AL-BAKERS, SAMPEDRO F, PEREZ-SOLER R: Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother. PharmacoL (1992) 30:365–369.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, SHIN DM, SIDDIK ZH etal.: Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. Clin. Cancer Res. (1997) 3:373–379.
   Google Scholar
• PEREZ-SOLER R, WALSH GL, SWISHER SG et al.: Phase II study of liposome-entrapped cisplatin-analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. Proc. Am. Soc. Clin. OncoL (1999) 18:421a (Abstract 1626).
   Google Scholar
• GELMON KA, TOLCHER A, DIAB AR et al.: Phase I study of liposomal vincristine. j Clin. OncoL (1999) 1b7:697–705.
   Google Scholar
• SARRIS AH, HAGEMEISTER F, ROMAGUERA J et al.: Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing Phase II trial. Ann OncoL (2000) 11: 69–72.
   PubMed Web of Science ®Google Scholar
• HENGGE UR, BROCKMEYER NH, BAUMANN M, REIMANN G, GOOS M: Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet (1993) 343:497.
   Google Scholar
• SIMPSON JK, MILLER RF, SPITTLE MF: Liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Clip. OncoL (1?. Coll. Radial.) (1993) 5:372–374.
   PubMedGoogle Scholar
• BOGNER JR, KRONAWITTER U, ROLINSKI B, TRUEBENACH K, GOEBEL F-D: Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi's sarcoma. j AIDS (1994) 7:463–468.
   PubMed Web of Science ®Google Scholar
• JAMES ND, COKER RJ, TOMLINSON D et al.: Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. Clin. OncoL (R. Coll. Radial.) (1994) 6:294–296.
   PubMedGoogle Scholar
• HARRISON M, TOMLINSON D, STEWART S: Liposomal entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. j Clin. OncoL (1995) 13:914–920.
   PubMed Web of Science ®Google Scholar
• GOEBEL F-D, GOLDSTEIN D, GOOS M, JABLONOWSKI H, STEWART JS: Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer (1996) 73:989–994.
   PubMed Web of Science ®Google Scholar
• STEWART JSW, JABLONOWSKI H, GOEBEL F-D et al.: Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposfs sarcoma. International Pegylated Liposomal Doxorubicin Study Group. Clin. arca (1998) 16:683–691.
   Google Scholar
• ••Randomised trial demonstratingsuperiority of liposomal doxorubicin to combination chemotherapy.
   Google Scholar
• NORTHFELT DW, DEZUBE B, THOMMES JA et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised Phase III clinical trial. ..J. Clin. arca (1998) 16:2445–2451.
   PubMed Web of Science ®Google Scholar
• ••Randomised trial demonstratingsuperiority of liposomal doxorubicin to combination chemotherapy.
   Google Scholar
• FISCHL MA, KROWN SE, O'BOYLE KP et al.: Weekly doxorubicin in the treatment of patients with AIDS-related Kaposfs sarcoma. AIDS Clinical Trials Group. AIDS (1993) 6:259–264.
   Google Scholar
• MUGGIA FM, HAINSWORTH JD, JEFFERS S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. Clin. arca (1997) 15:987–993.
   Google Scholar
• GORDON AN, GRANAI CO, ROSE PG et al.: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. I Clin. arca (2000) 18:3093–3100.
   Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K, PETERSON G, KULP B, BELINSON J: Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/ paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Cynecol. arca (2000) 78:369–372.
   PubMed Web of Science ®Google Scholar
• GORDON AN, FLEAGLE JT, GUTHRIE D et al.: Interim analysis of a Phase III randomized trial of Caelyx/Doxil (D) versus Topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proc. Am. Soc. Clin. arca (2000) 19:380a (Abstract 1504).
   Google Scholar
• ISRAEL VP, GARCIA AA, ROMAN L et al.: Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Cynecol arca (2000) 78:143–147.
   PubMed Web of Science ®Google Scholar
• RANSON MR, CARMICHAEL J, O'BYRNE K, STEWART S, SMITH D, HOWELL A: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicentre Phase II trial...J. Clin. arca (1997) 15:3185–3191.
   PubMed Web of Science ®Google Scholar
• LYASS 0, UZIELY B, BEN-YOSEF R et al.: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer (2000) 89:1037–1047.
   Google Scholar
• CAP ONIGRO F, COMELLA P, BUDILLON A et al.: Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Ann. arca (2000) 11:339–342.
   Google Scholar
• HARRINGTON KJ, LEWANSKI CR, NORTHCOTE AD et al.: Phase II study of pegylated liposomal doxorubicin (Caelyx) in patients with inoperable, locally advanced squamous cell cancer of the head and neck. Eur. j Cancer (2001) (In Press).
   Google Scholar
• WOLLINA U, GRAEFE T, KARTE K: Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. j Am. Acad. Dermata (2000) 42:40–46.
   PubMed Web of Science ®Google Scholar
• JUDSON I, RADFORD J, BLAY J-Y et al.: A randomised Phase II trial of Caelyx®/ Doxil® versus doxorubicin in advanced or metastatic soft tissue sarcomas (STS) - an EORTC Soft Tissue and Bone Sarcoma (STBSG) trial. Proc. Am. Soc. Clin. arca (1999) 18:541 (Abstract 2089).
   Google Scholar
• TOMA S, TUCCI A, VILLANI G, CARTENI G, SPADINI N, PALUMBO R: Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a Phase II study of the Italian Sarcoma Group (ISG). Anti-Cancer Res. (2000) 20:485–491.
   PubMed Web of Science ®Google Scholar
• RUFF P, MOODLEY SD, RAPOPORT BL etal.: Pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HCC). Proc. Am. Soc. Clin arca (2000) 19:268a (Abstract 1044).
   Google Scholar
• O'BRIEN M, HICKISH T, IVESON T et al.: Phase II study of Caelyx® (Doxil®; doxorubicin HC1 pegylated liposomal) in the treatment of small cell lung cancer (SCLC). Proc. Am. Soc. Gin arca (1998) 17:497 (Abstract 1913).
   Google Scholar
• ERNST DS, WINQUIST E, MOORE M, JONKER D, FRIEL C: Activity of pegylated liposomal doxorubicin (Caelyx) in advanced transitional cell carcinoma (TCC). Proc. Am. Soc. Clin arca (2000) 19:363a (Abstract 1431).
   Google Scholar
• DIETRICH J, FABEL-SCHULTE K, HAU P et al.: Liposomal doxorubicin (Caelyx) in the treatment of recurrent high- grade glioma - a Phasestudy. Proc. Am. Soc. Clin. arca (2000) 19:170a (Abstract 661).
   Google Scholar
• PENNINGTON K, GORDON M, PICUS J: A Phase II trial of liposomal doxorubicin (Doxil®) in the treatment of advanced renal cell cancer: A Hoosier Oncology Group (HOG) study. Proc. Am. Soc. Gin arca (1998) 17:339a (Abstract 1308).
   Google Scholar
• YIP D, HALFORD S, KARAPETIS C, STEGER A, KHAWAJA H, HARPER PA: Phase II trial of Caelyx Tm (Liposomal Doxorubicin, Doxil) in the treatment of advanced pancreatic cancer. Proc. Am. Soc. Clin. arca (1999) 18:306a (Abstract 1177).
   Google Scholar
• KOLETSKY A, JAHANZEB M, RADICE P et al.: Pegylated liposomal doxorubicin (PEG-LD) as second line treatment of advanced non-small cell carcinoma (NSCLC) after platinum-based therapy: A randomised Phase II trial. Proc. Am. Soc. Clin. arca (1999) 18:512a (Abstract 1976).
   Google Scholar
• RADICE P, JAHANZEB M, KOLETSKY A et al.: Weekly pegylated liposomal doxorubicin is extremely well tolerated as second line chemotherapy. Proc. Am. Soc. Clin. arca (1999) 18:520a (Abstract 2004).
   Google Scholar
• ELSON P, CHIDIAC T, BUDD GT etal.: Phase II trial of Doxil in advanced soft tissue sarcomas (STS). Proc. Am. Soc. Clin. arca (1998) 17:513a (Abstract 1979).
   Google Scholar
• SKUBITZ KM: Early results of pegylated liposomal doxorubicin (Doxil®) in refractory sarcoma. Proc. Am. Soc. Clin. arca (1998) 17:524a (Abstract 2013).
   Google Scholar
• HALM U, ETZRODT G, SCHIEFKE I et al.: A Phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann. arca (2000) 11:113–114.
   Google Scholar
• SAMANTAS E, KALOFONOS H, LINARDOU H etal.: Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study. Ann. arca (2000) 11:1395–1397.
   Google Scholar
• WOLLINA U, GRAEFE T, KAATZ M: Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. I Cancer Res. Clin. arca (2001) 127:128–134.
   PubMed Web of Science ®Google Scholar
• ISRAEL VK, JEFFERS S, BERNAL G et al.: Phase I study of Doxil (liposomal doxorubicin) in combination with paclitaxel. Proc. Am. Soc. Clin. (1998) 17:245 (Abstract 938).
   Google Scholar
• LANGLEY RE, CARMICHAEL J, WOLL PJ, MASON E, WELBANK H: Phase II trial to evaluate the safety and tolerability of Caelyx® in combination with paclitaxel in the treatment of metastatic cancer. Proc. Am. Soc. Clin. Oiled. (1998) 17:246a (Abstract 943).
   Google Scholar
• MOORE MR, SRINIVASIAH J, FEINBERG BA et al.: Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HC1 liposome injection (Doxil l plus paclitaxel (DT) in metastatic breast cancer. Proc. Am. Soc. Clin. (1998) 17:160a (Abstract 614).
   Google Scholar
• SCHWONZEN M, KURBACHER CM, MALLMANN P: Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anti-Cancer Drugs (2000) 11:681–685.
   PubMed Web of Science ®Google Scholar
• TOLIS CF, BRIASOULIS EC, TZAMAKOU E etal.: Phase I trial and interaction pharmacokinetics of pegylated-liposomal doxorubicin (Caelyx; Doxil) and weekly Taxol. Proc. Am. Soc. Clin. Oncol. (2000) 19:206a (Abstract 803).
   Google Scholar
• MALIK UR, SPARANO JA, WOLFFE A: Phase I trial of liposomal doxorubicin (Doxil) and docetaxel (Taxotere) in patients (PTS) with advanced breast cancer (ABC). Proc. Am. Soc. Clin. Oncol. (1998) 17:175a (Abstract 672).
   Google Scholar
• KLEIN P, LYASS 0, SORICH J et al.: Doxil plus cisplatin: combined results of two Phase I studies. Proc. Am. Soc. Clin. Oncol. (1998) 17:246a (Abstract 942).
   Google Scholar
• LAUFMAN LR, SPIRIDONIDIS CH, JONES JJ, RHODES VA, WALLACE K: Phase I trial of Doxil® plus vinorelbine (VNB) in patients (PTS) with advanced malignancies. Proc. Am. Soc. Clin. (1998) 17:246a (Abstract 944).
   Google Scholar
• RAMIREZ MR, MARCOM PK, SUTTON LM et al.: A Phase I/II study of Doxil and vinorelbine in metastatic breast cancer patients. Proc. Am. Soc. CBI]. Oncol. (1998) 17:169a (Abstract 650).
   Google Scholar
• HOLDER L, OVERMOYER B, SILVERMAN P, TRIPATHY D, MARRS N, TEITELBAUM AH: Doxil® and oral cyclophosphamide as first-linetherapy for patients with metastatic breast cancer (MBC): Preliminary results of a pilot trial. Proc. Am. Soc. Clin. Oncol. (1998) 17:146a (Abstract 556).
   Google Scholar
• TOBIAS DH, RUNOWICZ C, MANDELI J et al.: A Phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer. Proc. Am. Soc. Clin. Oiled. (2000) 19:392a (Abstract 1551).
   Google Scholar
• VOLM M, ORATZ R, PAVLICK A, FARRELL K, LEE J, MUGGIA F: A Phase I study of liposomal doxorubicin and temozolomide in patients with advanced cancer. Proc. Am. Soc. Clin. Oiled. (2000) 19:223a (Abstract 872).
   Google Scholar
• TSIARA SN, KAPSALI E, CHRISTOU L, PANTELI A, PRITSIVELIS N, BOURANTAS KL: Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur. Haematol. (2000) 65:118–122.
   PubMed Web of Science ®Google Scholar
• MADHAVAN S, NORTHFELT DW: Lack of vesicant injury following extravasation of liposomal doxorubicin. j. Natl. Cancer Inst. (1995) 87:1556–1557.
   PubMed Web of Science ®Google Scholar
• LOTEM M, HUBERT A, LYASS 0 et al.:Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch. Dermatol. (2000) 136:1475–1480.
   Google Scholar
• BERRY G, BILLINGHAM M, ALDERMAN E et al.: The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann. Oncol. (1998) 9:711–716.
   PubMed Web of Science ®Google Scholar
• SAFRA T, MUGGIA F, JEFFERS S et al.:Pegylated liposomal doxorubicin (doxifi: reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. (2000) 11:1029–1033.
   PubMed Web of Science ®Google Scholar
• SPEYER J, WASSERHEIT C. Strategies forreduction of anthracycline cardiac toxicity. Semi]. Oncol. (1998) 25:525–537.
   PubMed Web of Science ®Google Scholar
• GORDON KB, TAJUDDIN A, GUITART J, KUZEL TM, ERAMO LR, VON ROENN J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer (1995) 75:2169–2173.
   PubMed Web of Science ®Google Scholar
• VAIL DM, CHUN R, THAMM DH, GARRETT LD, COOLEY AJ, OBRADOVICH JE: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. CM. Cancer Res. (1998) 4:1567–1571.
   PubMed Web of Science ®Google Scholar
• COLBERN GT, MUSTERER R, HILLER AJ et al.: Treatment of palmar-plantar erythrodysaesthesia with pyridoxine or ergotamine: Effect on efficacy of Doxil in Lewis lung carcinoma. Proc. Am. Soc. Clin. Oncol. (1998) 17:238a (Abstract 913).
   Google Scholar
• LOPEZ AM, WALLACE L, DORR RT, KOFF M, HERSH EM, ALBERTS DS: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother. Pharmacol. (1999) 44:303–306.
   PubMed Web of Science ®Google Scholar
• COLBERN GT, STEINMETZ KL, MUSTERER R etal.: Amifostine reduces severity and incidence of Doxil-induced palmariplantar erythrodysesthesis in rats but does not reduce Doxil antitumour efficicay or alter pharmacokinetics in mice. Proc. Am. Soc. Clin. Oncol. (2000) 19:209a (Abstract 815).
   Google Scholar
• DEMARIO MD, VOGELZANG NJ, JANISCH L et al.: A Phase I study of liposome-formulated cisplatin (SPI-77®) given every 3 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (1998) 17:230a (Abstract 883).
   Google Scholar
• DEVORE RF, JOHNSON DH, STRUPP J et al.: Phase I trial of SPI-077 plus paclitaxel in patients with refractory non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (1999) 18:488a (Abstract 1881).
   Google Scholar
• HARRINGTON KJ, LEWANSKI CR, NORTHCOTE AD etal.: Phase I/II study of pegylated liposomal cisplatin (SPI-077') in patients with inoperable head and neck cancer. Ann. Oncol. (2001) (In Press).
   Google Scholar
• KNIGHT V, KOSHKINA NV, WALDREP JC, GIOVANELLA BC, GILBERT BE: Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol. (1999) 44:177–186.
   PubMed Web of Science ®Google Scholar
• KOSHKINA NV, KLEINERMAN ES, WAIDREP C et al.: 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. (2000) 6:2876–2880.
   PubMed Web of Science ®Google Scholar
• TARDI P, CHOICE E, MASIN D, REDELMEIER T, BALLY M, MADDEN TD: Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. (2000) 60:3389–3393.
   PubMed Web of Science ®Google Scholar
• THOMAS GM: Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Eng] J Med. (1999) 340:1198–1200.
   PubMed Web of Science ®Google Scholar
• COOPER JS, GUO MD, HERSKOVIC A et al.: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA (1999) 281:1623–1627.
   Google Scholar
• PIGNON JP, BOURHIS J, DOMENGE C, DESIGNE L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet (2000) 355:949–955.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, ROWLINSON-BUSZA G, USTER PS, WHITTAKER J, STEWART JSW: Stealth liposome encapsulated doxorubicin (SLED) and iododeoxyuridine (SLIUDR) as radiation sensitisers in head and neck squamous cell cancer xenograft tumours (HNSCCXT). Proc. Am. Soc. Clin Omni (1998) 17:230a (Abstract 881).
   Google Scholar
• HARRINGTON KJ, ROWLINSON-BUSZA G, SYRIGOS KN et al: Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumour xenograft model. Clin. Cancer Res. (2000) 6:4939–4949.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, ROWLINSON-BUSZA G, USTER PS, VILE RG, PETERS AM, STEWART JS: Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model. Int. j Radiat. Omni Biol. Phys. (2001) 49:1141–1148.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, ROWLINSON-BUSZA G, VILE RG, PETERS AM, STEWART JSW: The effect of irradiation on the biodistribution of radiolabelled pegylated liposomes in nude mice. Irm Radiat. Omni Biol. Phys. (2001) (In Press).
   Google Scholar
• MASTROBATTISTA E, KONING GA, STORM G: Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Deify. Rev. (1999) 40:103–127.
   PubMed Web of Science ®Google Scholar
• •Excellent review of immunoliposomes.
   Google Scholar
• HUANG A, KENNEL SJ, HUANG L: Interactions of immunoliposomes with target cells. J. Biol. Chem. (1983) 258:14034–14040.
   PubMed Web of Science ®Google Scholar
• OHTA S, IGARASHI S, HONDA A, SATO S, HANAI N: Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies. AntiCancer Res. (1993) 13:331–336.
   PubMed Web of Science ®Google Scholar
• VINGERHOEDS MH, STEERENBERG PA, HENDRIKS JJ etal.: Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br. J. Cancer (1996) 74: 1023–1029.
   Google Scholar
• SUZUKI S, INOUE K, HONGOH A, HASHIMOTO Y, YAMAZOE Y: Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. Br J. Cancer (1997) 76:83–89.
   PubMed Web of Science ®Google Scholar
• CROSASSO P, BRUSA P, DOSIO F et al: Antitumoural activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. I Pharm. Li. (1997) 86:832–839.
   Google Scholar
• PAGNAN G, MONTALDO PG, PASTORINO F et al: GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer (1999) 81:268–274.
   PubMed Web of Science ®Google Scholar
• KONING GA, MORSELT HW, VELINOVA MJ et al: Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells. Biochim. Biophys. Acta (1999) 1420:153–167.
   PubMed Web of Science ®Google Scholar
• KONING GA, GORTER A, SCHERPHOF GL, KAMPS JA: Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br. J. Cancer (1999) 80:1718–1725.
   PubMed Web of Science ®Google Scholar
• TSENG YL, HONG RL, TAO MH, CHANG FH: Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int. J. Cancer (1999) 80:723–730.
   PubMed Web of Science ®Google Scholar
• LOPES DE MENEZES DE, PILARSKI LM, BELCH AR, ALLEN TM: Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim. Biophys. Acta (2000) 1466:205–220.
   PubMed Web of Science ®Google Scholar
• ARAGNOL D, LESERMAN LD: Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Nati Acad. Sri. USA (1986) 83:2699–2703.
   PubMed Web of Science ®Google Scholar
• DERKSEN JT, MORSELT HW, SCHERPHOF GL: Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages. Biochim. Biophys. Acta (1988) 971:127–136.
   PubMed Web of Science ®Google Scholar
• HARDING JA, ENGBERS CM, NEWMAN MS, GOLDSTEIN NI, ZALIPSKY S: Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol) -grafted immunoliposomes. Biochim. Biophys. Acta (1997) 1327:181–192.
   PubMed Web of Science ®Google Scholar
• MARUYAMA K, TAKAHASHI N, TAGAWA T, NAGAIKE K, IWATSURU M: Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumours in vivo. FEBS Lett. (1997) 413:177–180.
   PubMed Web of Science ®Google Scholar
• LOPES DE MENEZES DE, PILARSKI LM, ALLEN TM: In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. (1998) 58:3320–3330.
   PubMed Web of Science ®Google Scholar
• BANKERT RB, YOKOTA S, GHOSH SK, MAYHEW E, JOU YH: Immunospecific targeting of cytosine arabinonucleoside-containing liposomes to the idiotype on the surface of a murine B-cell tumor in vitro and in vivo. Cancer Res. (1989) 49:301–308.
   PubMed Web of Science ®Google Scholar
• WU NZ, DAD, RUDOLL TL, NEEDHAM D, WHORTON AR, DEWHIRST MW: Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. (1993) 53:3765–3770.
   PubMed Web of Science ®Google Scholar
• •An important description of the mechanism of tumour targeting by liposomes.
   Google Scholar
• YUAN F, LEUNIG M, HUANG SK, BERK DA, PAPAHADJOPOULOS D, JAIN RK: Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. (1994) 54:3352–3356.
   PubMed Web of Science ®Google Scholar
• PARK JW, HONG K, CARTER P et al: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sri. USA (1995) 92:1327–1331.
   PubMed Web of Science ®Google Scholar
• GOREN D, HOROWITZ AT, ZALIPSKY S, WOODLE MC, YARDEN Y, GABIZON A: Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J. Cancer (1996) 74:1749–1756.
   PubMed Web of Science ®Google Scholar
• AHMAD I, LONGENECKER M, SAMUEL J, ALLEN TM: Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. (1993) 53:1484–1488.
   PubMed Web of Science ®Google Scholar
• •Early description of the activity of pegylated immunoliposomes.
   Google Scholar
• STRAUBINGER RIVI, LOPEZ NG, DEBS RJ, HONG K, PAPAHADJOPOULOS D: Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. (1988) 48:5237–5245.
   PubMed Web of Science ®Google Scholar
• NASSANDER UK, STEERENBERG PA, POPPE H et al.: In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res. (1992) 52:646–653.
   PubMed Web of Science ®Google Scholar
• CROOP JM, GROS E HOUSMAN DE: Genetics of multidrug resistance. J. Chu. Invest. (1988) 81:1303–1309.
   PubMed Web of Science ®Google Scholar
• BRADLEY G, LING V: P-glycoprotein, multidrug resistance and tumour progression. Cancer Metastasis Rev. (1994) 13:223–233.
   PubMed Web of Science ®Google Scholar
• KAYE SB: Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Cum: Opirr. arca (1998) 10\(Suppl. 1):515–19.
   Google Scholar
• FOJO AT, SHEN DW, MICKLEY LA, PASTAN I, GOTTESMAN MM: Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J. Chu. Duca. (1987) 5:1922–1927.
   Google Scholar
• GOLDSTEIN LJ, GALSKI H, FOJO A et al.: Expression of a multidrug resistance gene in human cancers. J. Nati Cancer Inst. (1989) 81:116–124.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN LJ: MDR1 gene expression in solid tumours. Eur. J. Cancer (1996) 32A:1039–1050.
   PubMed Web of Science ®Google Scholar
• WANG CS, LARUE H, FORTIN A, GARIEPY G, TETU B: Mdrl mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res. Treat (1997) 45:63–74.
   PubMed Web of Science ®Google Scholar
• VERRELLE E MEISSONNIER F, FONCK Y et al.: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Nati Cancer Inst. (1991) 83:111–116.
   PubMed Web of Science ®Google Scholar
• WALLNER J, DEPISCH D, HOPFNER M et al.: MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur. J. Cancer (1991) 27:1352–1355.
   PubMed Web of Science ®Google Scholar
• WALLNER J, DEPISCH D, GSUR A, GOTZL M, HAIDER K, PIRKER R: MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer (1993) 71:667–671.
   PubMed Web of Science ®Google Scholar
• LINN SC, GIACCONE G, VAN DIEST PJ et al.: Prognostic relevance of P-glycoprotein expression in breast cancer. Ann. Duca (1995) 6:679–685.
   Google Scholar
• THIERRY AR, JORGENSEN TJ, FORST D, BELLI JA, DRITSCHILO A: RAHMAN A. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Commun. (1989) 1:311–316.
   Google Scholar
• •Initial report of the ability of liposomes to modulate multidrug resistance.
   Google Scholar
• RAHMAN A, HUSAIN SR, SIDDIQUI J et al.: Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl. Cancer Inst. (1992) 84:1909–1915.
   PubMed Web of Science ®Google Scholar
• THIERRY AR, DRITSCHILO A, RAHMAN A: Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem. Biophys. Res. Commun. (1992) 187:1098–1105.
   PubMed Web of Science ®Google Scholar
• THIERRY AR, VIGE D, COUGHLIN SS, BELLI JA, DRITSCHILO A, RAHMAN A: Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. (1993) 7:572–579.
   PubMed Web of Science ®Google Scholar
• MICHIELI M, DAMIANI D, ERMACORA A et al.: Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Br j Haematol. (1999) 106:92–99.
   PubMed Web of Science ®Google Scholar
• POUJOL S, TILLEUL E ASTRE C, MARTEL P, FABBRO M, PINGUET F: Effect of mitoxantrone liposomes on multidrug-resistant breast cancer cells. Anti-Cancer Res. (1999) 19:3327–3331.
   PubMed Web of Science ®Google Scholar
• WANG Y, EKSBORG S, LEWENSOHN R, LINDBERG A, LILIEMARK E: In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells. Anti-Cancer Drugs (1999) 10:921–928.
   PubMed Web of Science ®Google Scholar
• SARGENT JM, ELGIE AW, WILLIAMSON CJ, LEWANDOWICZ GM, TAYLOR CG: In vitro sensitivity to the liposomal preparation, DaunoXome in CLL. Anti-Cancer Res. (1999) 19:3253–3257.
   PubMed Web of Science ®Google Scholar
• KRISHNA R, MAYER LD: Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. (1997) 57:5246–5253.
   PubMed Web of Science ®Google Scholar
• KRISHNA R, ST-LOUIS M, MAYER LD: Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Intl Cancer (2000) 85:131–141.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, GOLUB RM, STINSON TJ et al.: Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1998) 18:460–465.
   PubMedGoogle Scholar
• HJORTSBERG C, PERSSON U, LIDBRINK E, BENNETT C: Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Acta arca (1999) 38:1063–1067.
   Google Scholar
• EMBREE L, GELMON K, TOUCHER A etal.: Pharmacokinetic behaviour of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother. Pharmacol. (1998) 41:347–352.
   Google Scholar